(Q38076330)

English

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

scientific article published on 24 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

1 reference

Europe PubMed Central

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Y G Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

S Hahn

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

T J Oh

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

K S Park

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Y M Cho

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

24 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

696-708

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Diagnosis and classification of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Epidemic obesity and type 2 diabetes in Asia

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Decreased insulin secretion but not insulin sensitivity in normal glucose tolerant Thai subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

K-cells and glucose-dependent insulinotropic polypeptide in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Impaired regulation of the incretin effect in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Mechanisms linking obesity to insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Cardiovascular risk profile assessment in glucose-intolerant Asian individuals--an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Predictive Properties of Impaired Glucose Tolerance for Cardiovascular Risk Are Not Explained by the Development of Overt Diabetes During Follow-Up

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Larger Amounts of Visceral Adipose Tissue in Asian Americans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Reduced Incretin Effect in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2827-3

21 January 2018

Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes in Asia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23344728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-012-2827-3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38076330&oldid=2201240965"